title: Factors influencing remission phase in children with type 1 diabetes mellitus.
abstract: Type 1 diabetes mellitus (DM) is characterized by selective and progressive autoimmune destruction of beta-cells of the pancreas in genetically susceptible individuals. This autoimmune process takes years before the patient eventually develops clinical DM. Over the course of the disease, some patients regain their ability to secrete endogenous insulin to some extent for a period of few months to years. This partial remission phase has drawn a lot of attention since it offers a window of opportunity to intervene in an attempt to restore pancreatic beta-cell function or to prevent development of the disease in the prediabetic population at risk. Several factors, including age, sex, pubertal status, metabolic findings at the time of presentation, HLA types, presence of diabetes-associated autoantibodies, have been recognized to affect the likelihood of partial or complete remission in children with type 1 DM. Several interventions in patients with new-onset type 1 DM have been tried, including oral nicotinamide and immunomodulatory and immunosuppressive treatments, in an attempt to preserve beta-cell function and to promote or prolong the remission phase, but no conclusive data have been obtained so far. This review summarizes current knowledge on the factors that possibly influence the remission phase in children with type 1 DM.
authors.affiliation: Department of Pediatric Endocrinology and Adolescence, Dokuz Eylül University, Inciralti, Izmir, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Büyükgebiz
authors.forename: A P
authors.initials: AP
authors.lastname: Cemeroglu
authors.forename: E
authors.initials: E
authors.lastname: Böber
authors.forename: A
authors.initials: A
authors.lastname: Mohn
authors.forename: F
authors.initials: F
authors.lastname: Chiarelli
mesh_terms: D000375:Aging / Q000502:physiology; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007167:Immunotherapy; D007328:Insulin / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000503:physiopathology; D011627:Puberty / Q000502:physiology; D012075:Remission, Spontaneous; D012727:Sex Characteristics
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin